Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension

According to the results from a cohort of over 400 patients with PV or ET, the use of renin-angiotensin inhibitors (RASi) showed a protective effect from thrombotic adverse events among patients with hypertension (HR 0.46; 95% CI 0.21–0.98, p = 0.04) and in the subgroup of thrombotic high-risk score patients (HR 0.49; 95% CI 0.24–1.01, p = 0.04). Specifically, patients with ET and a high risk of thrombosis benefited most from RASi treatment (HR 0.27; 95% CI 0.07–1.01, p = 0.03).